DOV-216303 HCl | CAS# 86215-36-3 (HCl) | triple reuptake inhibitor, or serotonin-norepinephrine-dopamine reuptake inhibitor

MedKoo Cat#: 413911 | Name: DOV-216303 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DOV-216303 HCl is an antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and Dov terminated their relationship in December 2006. It is a triple reuptake inhibitor, or serotonin-norepinephrine-dopamine reuptake inhibitor

Chemical Structure

DOV-216303 HCl

CAS#86215-36-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 413911

Name: DOV-216303 HCl

CAS#: 86215-36-3 (HCl)

Chemical Formula: C11H12Cl3N

Exact Mass: 263.0035

Molecular Weight: 264.57

Elemental Analysis: C, 49.94; H, 4.57; Cl, 40.20; N, 5.29

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

86215-36-3 (HCl) 66504-40-3 (free base)

Synonym

DOV-216303 HCl; DOV-216303 hydrochloride; DOV 216,303; DOV216303

IUPAC/Chemical Name

3-Azabicyclo(3.1.0)hexane, 1-(3,4-dichlorophenyl)-, hydrochloride (1:1)

InChi Key

KAGBHVBIOJBGBD-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H11Cl2N.ClH/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11;/h1-3,8,14H,4-6H2;1H

SMILES Code

ClC1=CC=C(C23CNCC2C3)C=C1Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 264.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sørensen G, Husum H, Brennum LT, Bundgaard C, Montezinho LC, Mørk A, Wörtwein G, Woldbye DP. Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse. Basic Clin Pharmacol Toxicol. 2014 Jun;114(6):451-9. doi: 10.1111/bcpt.12182. Epub 2014 Jan 16. PMID: 24314270. 2: Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 Summer;12(2):123-34. doi: 10.1111/j.1527-3458.2006.00123.x. PMID: 16958986; PMCID: PMC6494125. 3: Beer B, Stark J, Krieter P, Czobor P, Beer G, Lippa A, Skolnick P. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol. 2004 Dec;44(12):1360-7. doi: 10.1177/0091270004269560. PMID: 15545306. 4: Chu TH, Cummins K, Stys PK. The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice. Neurosci Lett. 2018 May 14;675:1-6. doi: 10.1016/j.neulet.2018.03.050. Epub 2018 Mar 22. PMID: 29578004. 5: Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104. doi: 10.1016/s0014-2999(03)01310-4. PMID: 12586204. 6: Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. doi: 10.1124/jpet.107.133132. Epub 2007 Dec 18. PMID: 18089843. 7: Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, Schreiber R, Hanania T, Snoeren EM, Waldinger M, Olivier B. The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol. 2008 Dec;18(12):908-16. doi: 10.1016/j.euroneuro.2008.07.011. Epub 2008 Sep 11. PMID: 18789657. 8: Prins J, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Olivier B, Korte SM. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats. Pharmacol Biochem Behav. 2011 Jan;97(3):444-52. doi: 10.1016/j.pbb.2010.10.001. Epub 2010 Oct 8. PMID: 20934452. 9: Prins J, Denys DA, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Groenink L, Olivier B, Korte SM. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol. 2010 May 10;633(1-3):55-61. doi: 10.1016/j.ejphar.2010.02.009. Epub 2010 Feb 12. PMID: 20153745. 10: Prins J, Kenny PJ, Doomernik I, Schreiber R, Olivier B, Mechiel Korte S. The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats. Eur J Pharmacol. 2012 Oct 15;693(1-3):51-6. doi: 10.1016/j.ejphar.2012.07.047. Epub 2012 Aug 21. PMID: 23010469.